Table 2.
Number of statin users 2004–2006 among participants in population-based studies 2000–2002, who reported never use of statins at baseline
| Non-CVD/diabetes group | CVD/diabetes group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Education† | n | % | Crude RR (n = 19 557) | 95% CI | Adjusted RR‡ (n = 18 547) | 95% CI | n | % | Crude RR (n = 655) | 95% CI | Adjusted RR‡ (n = 609) | 95% CI |
| Men 40–41, 45–46 | ||||||||||||
| Low | 57 | 8.1 | 1.00 | Ref | 1.00 | Ref | 7 | 35.0 | 1.00 | Ref | 1.00 | Ref |
| Middle | 228 | 6.8 | 0.84 | 0.64, 1.11 | 0.97 | 0.73, 1.29 | 20 | 23.8 | 0.68 | 0.33, 1.39 | 0.67 | 0.29, 1.57 |
| High | 95 | 4.9 | 0.61 | 0.45, 0.84 | 0.94 | 0.68, 1.31 | 4 | 16.0 | 0.46 | 0.15, 1.35 | 0.59 | 0.22, 1.58 |
| Total | 380 | 6.4 | 31 | 24.0 | ||||||||
| Men 59–61 | ||||||||||||
| Low | 129 | 20.5 | 1.00 | Ref | 1.00 | Ref | 36 | 49.3 | 1.00 | Ref | 1.00 | Ref |
| Middle | 243 | 18.0 | 0.88 | 0.73, 1.06 | 0.90 | 0.74, 1.09 | 46 | 43.8 | 0.89 | 0.65, 1.22 | 0.92 | 0.65, 1.29 |
| High | 131 | 16.0 | 0.78 | 0.63, 0.97 | 0.84 | 0.67, 1.05 | 26 | 49.1 | 0.99 | 0.69, 1.43 | 1.09 | 0.74, 1.60 |
| Total | 503 | 18.0 | 108 | 46.8 | ||||||||
| Women 40–41, 45–46 | ||||||||||||
| Low | 43 | 5.7 | 1.00 | Ref | 1.00 | Ref | 11 | 34.4 | 1.00 | Ref | 1.00 | Ref |
| Middle | 159 | 3.9 | 0.68 | 0.49, 0.95 | 1.02 | 0.71, 1.47 | 12 | 19.7 | 0.57 | 0.28, 1.15 | 0.66 | 0.32, 1.35 |
| High | 63 | 2.3 | 0.41 | 0.28, 0.59 | 1.01 | 0.66, 1.56 | 8 | 23.5 | 0.68 | 0.31, 1.49 | 1.20 | 0.48, 3.03 |
| Total | 265 | 3.5 | 31 | 24.4 | ||||||||
| Women 59–61 | ||||||||||||
| Low | 136 | 16.7 | 1.00 | Ref | 1.00 | Ref | 19 | 30.2 | 1.00 | Ref | 1.00 | Ref |
| Middle | 250 | 15.0 | 0.90 | 0.74, 1.09 | 1.13 | 0.91, 1.37 | 24 | 28.9 | 0.96 | 0.58, 1.59 | 1.15 | 0.69, 1.92 |
| High | 86 | 11.0 | 0.66 | 0.51, 0.85 | 0.97 | 0.75, 1.26 | 9 | 40.9 | 1.36 | 0.72, 2.54 | 1.94 | 0.98, 3.81 |
| Total | 472 | 14.4 | 52 | 31.0 | ||||||||
| Total – adjusted for sex and age | ||||||||||||
| Low | 365 | 12.6 | 1.00 | Ref | 1.00 | Ref | 73 | 38.8 | 1.00 | Ref | 1.00 | Ref |
| Middle | 880 | 8.4 | 0.86 | 0.77, 0.96 | 1.00 | 0.89, 1.12 | 102 | 30.6 | 0.83 | 0.65, 1.06 | 0.94 | 0.73, 1.21 |
| High | 375 | 6.0 | 0.64 | 0.55, 0.73 | 0.91 | 0.79, 1.05 | 47 | 35.1 | 0.94 | 0.70, 1.26 | 1.35 | 1.00, 1.81 |
| Total | 1620 | 8.3 | 222 | 33.9 | ||||||||
Crude and adjusted relative risk (RR) of starting statin treatment in two subgroups stratified by age and sex.
†
Education: low, no, primary or lower secondary; middle, higher secondary or high school; high, college/university.
‡
Adjusted for serum total cholesterol and high-density lipoprotein-cholesterol, systolic blood pressure, treatment for hypertension, body mass index, family history of coronary heart disease, daily smoking, physical activity, marital status and county of residence. Adjusted values were based on participants with complete data.